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Abstract. Human herpesvirus 6A and 6B (HHV-6A and HHV-6B) have been noted since their 
discovery for their T-lymphotropism. Although it has proven difficult to determine the extent to 
which HHV-6A and HHV-6B are involved in the pathogenesis of many diseases, evidence 
suggests that primary infection and reactivation of both viruses may induce or contribute to the 
progression of several lymphoproliferative disorders, ranging from benign to malignant and 
including infectious mononucleosis-like illness, drug induced hypersensitivity syndrome/drug 
reaction with eosinophilia and systemic symptoms (DIHS/DRESS), and nodular sclerosis 
Hodgkin’s lymphoma. Herein, we discuss the conditions associated with the lymphoproliferative 
capacity of HHV-6, as well as the potential mechanisms behind them. Continued exploration on 
this topic may add to our understanding of the interactions between HHV-6 and the immune 
system and may open the doors to more accurate diagnosis and treatment of certain 
lymphoproliferative disorders.  
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Introduction. Human herpesvirus 6A and 6B 
(HHV-6A and HHV-6B), collectively known as 
HHV-6, are a pair of closely related 
betaherpesviruses of the genus Roseolovirus with 
lymphocytic tropism and immunomodulatory 
capabilities.1,2,3 HHV-6A was discovered in the 
peripheral blood mononuclear cells (PBMCs) of 
patients with AIDS-related lymphomas and other 
lymphoproliferative disorders in the latter part of 
the 1980s, and its T cell tropism was established in 
short order.1,4-6 Early investigations found that the 
available HHV-6 isolates could be split into two 
distinct variants, with HHV-6 Type A 
preferentially infecting immature T cells and Type 
B infecting mature T cells.2,7 These initial findings 
were followed by detection of HHV-6 antigen and 
DNA in the lymph nodes of patients with 
lymphoproliferative disorders and autopsy 
specimens,8-12 and a possible role for HHV-6 in 
lymphomas was examined, with some compelling 
results but no consensus.13-15 Although the virus 
has been implicated in a range of 
lymphoproliferative disorders, efforts are still 
underway to elucidate the pathogenic roles of 
HHV-6 in these conditions. The ubiquitous nature 
of the virus was recognized early on as a challenge 
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in identifying its role in the disorders in which it 
has been implicated, as its DNA can be found in 
the peripheral blood of healthy donors and low 
level reactivation may occur without clinical 
manifestations. Consequently, serological studies 
serve primarily to screen patients for HHV-6 
infection, while the most conclusive results are 
gained through the use of quantitative PCR, 
staining techniques applied to tissue samples, and 
through comparison with carefully selected 
controls. With the technical advancements and 
growing understanding of the effects of HHV-6 on 
the immune response, investigators are continuing 
to learn about the potential for HHV-6 to trigger 
lymphoproliferative disorders and the possible 
mechanisms behind it.  
 
Interactions between HHV-6 and the Immune 
System. HHV-6A and B infect hematopoietic 
stem cells (CD34+, CD32+), cord blood cells, and 
several immune cell populations in vitro and in 
vivo, including T lymphocytes, NK cells,16 
monocytes and macrophages,17,18 and dendritic 
cells,19 and HHV-6A has also been found to infect 
EBV-immortalized B cells.20 However, as the two 
species utilize different cellular receptors and 
impact chemokine/cytokine signaling in different 
ways, their tropism differs. This matter is further 
complicated as the presence of cellular receptors 
for HHV-6 does not guarantee infection of such 
cells in tissues.21 Viral DNA is found in 9-25% of 
peripheral blood mononuclear cells (PBMCs) from 
healthy donors,13,22 and HHV-6B is found more 
frequently than HHV-6A, which has been detected 
in the PBMCs of 3-10% of healthy individuals.13 
In most healthy adults, a T cell response to HHV-6 
is present,23 but fewer than 0.12% of CD4+ T cells 
in PBMC samples are reactive to HHV-6,24 and 
fewer than 1 in 105 CD8+ T cells in PBMCs are 
HHV-6-specific.25 Reactivation of HHV-6 occurs 
during T cell activation by various stimuli, 
including endotoxins, endocrine stimulation, 
certain cytokines, and food components (e.g. 
agglutinins, phorbol esters etc.). 
Immunosuppressive conditions, including those 
involving stress, transient immunosuppression, 
and/or stimulation resulting from infection with 
other viruses such as measles virus, support the 
persistent activity of HHV-6 once reactivated. 
Similar to EBV infections, persistent HHV-6 
activity can also be found after organ and 
hematopoietic stem cell transplantation. 
    As our understanding of HHV-6A and B has 
grown, their immunomodulatory activities have 
emerged as key contributors to many of the 
clinical manifestations linked to HHV-6 infection. 
HHV-6 infection is most commonly associated 
with exanthema subitum (roseola infantum),26 a 
manifestation of primary infection that occurs 
during early childhood. Intense reactivation of the 
virus is frequently observed in the transplantation 
setting, resulting in a host of complications post- 
solid organ and hematopoietic stem cell 
transplantation (HSCT). These conditions, as well 
as others associated with HHV-6 infection and 
reactivation, are often mediated to a great extent 
by the immune response to the virus and by the 
effects of the virus on various immune cell 
populations and cytokine/chemokine expression. 
The influences exerted by HHV-6A/HHV-6B 
differ by species, but both trigger inflammatory 
reactions while also employing mechanisms by 
which they can suppress an immune response and 
avoid detection.  
In vitro experimentation has demonstrated that 
HHV-6B and HHV-6A induce 
myelosuppression,27,28 infection of T cells and 
PBMCs inhibit immune responses against a 
tuberculin protein derivative or mumps antigen,29 
and infection of PBMCs results in reduced IL-2 
mRNA and protein synthesis- 50% less than 
mock-infected cells- sharply reducing cellular 
proliferation and indicating that the functions of T 
cells are suppressed.30 In the clinical setting, 
thymic atrophy and severe T lymphocytopenia 
have been reported,31-33 and in transplant 
recipients, delayed engraftment, 
myelosuppression,34 and graft failure35 have been 
known to occur in response to active HHV-6. An 
inverse correlation has been identified between 
reconstitution of CD4+ cells after HSCT and 
reactivation of HHV-6,36 as well as CD3+ cells37 
and CD8+ cells,38 and indeed, proliferation of 
lymphocytes has been inhibited by persistent 
HHV-6 infections after allo-HSCT.39 However, 
transplantation of cord blood, which is associated 
with a higher risk of HHV-6 reactivation and 
higher HHV-6 DNAemia40 compared to 
transplantation of other sources of hematopoietic 
stem cells, have also been found to have faster 
reconstitution of B lymphocytes with higher B cell 
counts, a phenomenon that has been hypothesized 
to arise as a result of an immune response against 
viral reactivation.40 As immune suppression 
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enables HHV-6 to better avoid detection and 
clearance, this phenomenon is advantageous for 
the persistence of the virus, but proliferation of 
infected lymphocytes may also be beneficial for its 
dissemination. Accordingly, immune suppression 
and immune activation are but two sides of the 
same coin during HHV-6 infection. When either 
suppression or proliferation is unchecked, severe 
clinical manifestations may result.  
Both HHV-6A and HHV-6B are able to affect 
chemokine/cytokine pathways, which are 
dysregulated in lymphoproliferative disorders. 
Infection by either virus impairs production of IL-
12 in macrophages41 and in dendritic cells,42 which 
may allow the viruses to suppress activation of 
cytotoxic effectors. In combination with lower IL-
2 expression,30 TNF-alpha, IL-1beta, IL-8, and IL-
15 have been found to be upregulated,43,44,45 
coinciding with a shift from a Th1 to Th2 cytokine 
profile. HHV-6A infection of astrocytes in patients 
with glioma has been associated with significantly 
upregulated TGF-beta, IL-6, and IL-8,46 and in 
vitro, HHV-6B infection of astrocytes has 
increased production of the proinflammatory 
cytokines IL-6 and IL-1beta.47 Notably, cytokine 
expression patterns vary temporally and in relation 
to the infected cell’s environment. IL-10, IL-11, 
and other anti-inflammatory mediators, for 
example, are expressed at high levels after 
exposing HHV-6 infected astrocytes to 
proinflammatory cytokines.48 
Viral proteins are also integral to HHV-6-
mediated immunomodulation. The HHV-6B 
encoded chemokine U83B induces chemotaxis and 
activation of leukocytes expressing CCR2, which 
is expressed under proinflammatory conditions.49 
Similarly, endometrial epithelial cells infected 
with HHV-6A have shown increased cell surface 
expression of CCL2, IP-10, and CCL26.50 On the 
other hand, the U83A chemokine (HHV-6A-
specific), as well as the U51A chemokine receptor, 
target CCR5/CCL5 (RANTES),51 another 
receptor/ligand pair involved in inflammation, 
resulting in down-modulation of their activity. 
U51A also binds four other inflammatory 
modulating chemokines that bind to and stimulate 
several immune cell populations, including B and 
T lymphocytes- CCL2, CCL7, CCL11, and 
CCL13- and the inflammatory cells expressing the 
U51A receptor exhibit chemotaxis toward, and 
internalization of, target chemokines.52 In contrast, 
primary HHV-6B infection results in upregulation 
of CCL2, CXCL11, CXCL10, and CXCL16.53 
Another mechanism by which the pair of 
viruses affect their host cells is the alteration of 
cell membrane fluidity and the dysregulation of 
cellular receptors.54,55 Both species downregulate 
MHC class I56,57 and CD46, which may result in 
activation of autologous complement and cellular 
damage in lymphoid tissue and beyond,58 and 
HHV-6A impairs expression of the T cell 
receptor/CD3 complex at the cell membrane, 
rendering the affected cells ineffective in 
responding to antigen-presenting cells.4,59,60 In 
addition, HHV-6A triggers expression of CD4 
mRNA and protein production in CD4 negative 
NK16 and T cells61 and can reduce the cytotoxicity 
of CD4+ T cells.62 Both species interact with toll-
like receptors and may exert their effects on 
cytokine/chemokine expression and the Th1/Th2 
balance through them.63-67 
 
Benign/Reactive Lymphoproliferative 
Disorders. Primary HHV-6B infection was 
identified as a causative agent of exanthema 
subitum (roseola infantum) in 1988, when the 
onset of the illness was linked to HHV-6 
seroconversion, and the presence of viral antigen 
was observed in patients’ lymphocytes.26 In some 
cases observed by Krueger et al., exanthema 
subitum was also seen during primary HHV-6A 
infection.68 In addition to the characteristic rash, 
fever, and occasionally febrile seizures and 
encephalitis,69,70 children with exanthema subitum 
can experience lymphadenopathy, relative 
lymphocytosis with increased CD38+ (immature) 
T cells, and hepatomegaly.69,71,72  
Thrombocytopenia, neutropenia, and leukopenia 
are commonly found as well.73 Notably, reactive 
“atypical” lymphocytes and hemophagocytosis 
may be observed in bone marrow,74,75 and a 
mononucleosis-like illness, with reactive 
lymphocytosis and liver dysfunction, has been 
described.76 Two unique cases documenting HHV-
6 infection with unusual lymphoproliferation in 
very young children have been reported: One 
infant, 7 months old, died suddenly after 
developing otitis media, and HHV-6 was found by 
PCR in tissue samples and in atypical lymphoid 
infiltrate via ISH.77 Abnormal, inflammatory 
lymphocytic infiltration was present in the liver, 
kidney, heart, spleen, bone marrow, and lymph 
nodes of the child, and interstitial pneumonitis was 
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reported. In the other case, a 2-week-old with 
HHV-6 DNA present in PBMCs, and who perhaps 
had congenital HHV-6, developed bone marrow 
cell proliferation, hypersensitivity to granulocyte-
macrophage colony-stimulating factor (GM-CSF), 
hepatosplenomegaly, and was thought to have 
juvenile myelomonocytic leukemia. However, the 
symptoms resolved.78 Generally, lympho-
proliferative responses during primary infection 
are limited in scope and resolve without issue. 
After primary infection, HHV-6A and HHV-6B 
remain latent in many organs, including the heart, 
lungs, gastrointestinal tract, and the brain, in 
addition to circulating lymphocytes. In 
immunocompetent individuals, low level 
reactivation may occur without major clinical 
symptoms. In those with immune deficiencies,79 
incomplete clearance and persistent activation 
cause various clinical diseases (e.g. post-transplant 
syndromes, autoimmune disorders etc.) During 
persistent or frequently recurrent reactivation in 
immune deficient persons (which is usually the 
case in studying adult patients), the virus has been 
associated with generalized reactive 
lymphadenopathy lasting for several days to 
several weeks.80-84 Among patients with reactive 
lymphadenopathy, scattered positivity (less than 
1% of total cells) when staining for the HHV-6 
antigens p101K, gp106, and gp116, has been 
observed among cells, namely plasma cells and 
histiocytes, from lymph node biopsies.85 The virus 
has been detected by PCR in PBMCs at a higher 
prevalence among patients with 
lymphoproliferative disorders than in healthy 
volunteers,86 and in Brazilian patients with 
lymphadenopathy and fever (but without skin 
rash), 8.7% had active HHV-6 infection (plasma 
viremia).87 While these results indicate that HHV-
6 may contribute to reactive lymphadenopathy, 
they may not implicate HHV-6 as the sole virus 
involved in its development, as it is difficult to 
rule out its reactivation in response to a different 
underlying cause of lymphadenopathy, including 
infections by other viruses. However, strong 
evidence of a role for HHV-6 in chronic/recurrent 
lymphadenopathy, backed by immune-
histochemical staining- a more specific technique- 
has been reported. Of 111 cases of benign/reactive 
lymphadenopathies with unknown etiology in a 
recent study, 7 (6.3%) demonstrated 
recurrent/chronic behavior, and intense staining 
for HHV-6B was detected in follicular dendritic 
cells in all cases (Figure 1).88 
 
Figure 1. HHV-6B in chronic/recurrent benign lymphadenopathy. (A–D) Histological and immunohistochemical examinations on 
lymph node tissues. Retained normal lymph node architecture with follicular hyperplasia and concurrent mild paracortical expansion was 
documented on haematoxylin/eosin staining. The lymph node follicles were enlarged and numerous. There was considerable variation in the 
size and shape of the follicles. Most of them retained a round to oval structure, without coalescence and with a conserved mantle zone 
surrounding the enlarged follicles (A, magnification ×100). An intense immunopositive staining with HHV-6B-specific p101K antibody was 
demonstrated in follicular dendritic cells (FDCs) of germinal centers in the majority of hyperplastic follicles, concurrently with scattered 
positivity of interfollicular cells [magnification ×100 (B), ×200 (C)]. Immunohistochemical reaction for HHV‐6A (early antigen p41/38) was 
invariably negative on lymph node tissues (D, magnification ×400) (Forghieri et al. 2016).88 
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    In contrast, only three non-recurrent/chronic 
cases showed staining for HHV-6B in germinal 
centers of follicular dendritic cells, and 7 others 
showed scattered positivity in cells of 
interfollicular areas. Control lymph node tissues 
(n=134), which were obtained from patients with 
benign lymphadenopathy with known etiology- 
including other infections, solid cancer without 
metastasis, sarcoidosis, Kikuchi-Fujimoto disease, 
Wegener granulomatosis, dermatopathic 
lymphadenopathy, and unspecified autoimmune 
disorders- or malignant tumors, were negative for 
HHV-6. While recurrent or chronic activity is not 
usually observed in reactive/benign conditions, it 
is more commonly found in atypical or malignant 
disorders.89 Although atypical lymphocytosis was 
not observed and there were no systemic 
symptoms, characteristics of abnormal/malignant 
lymph nodes, including irregular margin and 
hypoechoic center, were noted among the HHV-
6+ patients with chronic/recurrent 
lymphadenopathy. Taken together, the data 
suggest that HHV-6 may primarily be involved in 
prompting benign lymphoproliferative conditions 
of a certain type, and that the features discussed by 
Forghieri et al. may prove to be useful in 
differentiating between HHV-6-associated 
lymphoproliferation and that caused by other 
agents.88 
 
Rosai-Dorfman Disease. HHV-6 has been 
implicated as a trigger for several specific 
benign/reactive lymphoproliferative disorders, 
including Rosai-Dorfman (RD) disease. The first 
report of a possible association between the virus 
and development of RD described the detection of 
HHV-6 in involved tissues by ISH in the majority 
of a small cohort of patients (n=9).90 HHV-6B 
DNA was later identified using PCR and Southern 
blotting in the skin of a patient with RD presenting 
as giant lesions of granuloma annulare with 
multiple soft tissue tumors.91 The patient did not 
experience spontaneous clearing, which is usually 
observed for this disease. Notably, the HHV-6 late 
antigen p101k was detected in the lymph nodes of 
two RD patients (of two tested) in a pattern similar 
to that noted in the cases of chronic/recurrent 
lymphadenopathy described previously.85,88 In 
particular, intense staining was noted in follicular 
dendritic cells of reactive germinal centers in areas 
of normal lymph node architecture. Moreover, 
gp106 staining of many abnormal histiocytes 
within distended sinuses was observed, with an 
intense granular positive reaction in the cytoplasm, 
while weak positivity was observed for both 
antibodies in few plasma cells. In comparison, the 
lymph node biopsies from five cases of florid 
follicular hyperplasia, four cases with a 
predominantly paracortical lesion, four cases with 
sinus histiocytosis, and one histiocytic necrotizing 
lymphadenitis were all HHV-6 positive by PCR, 
but only isolated plasma cells and histiocytes, 
most often scattered in interfollicular areas, were 
positive for late antigens by IHC (<1% of cells in 
the lymph node).85 Few granulocytes were positive 
in the dilated sinuses of 2/4 cases with sinus 
histiocytosis. HHV-6B late antigen was also found 
by IHC in the lesion of a young boy with 
extranodal renal RD, a rare manifestation of the 
disease.92 It may be the case that only a subset of 
RD cases are associated with HHV-6,93 but the 
distinctive pattern of late antigen expression, 
indicating active infection in the follicular 
dendritic cells of germinal centers argues for the 
involvement of reactivated HHV-6 in the 
development of some cases of RD, especially as 
the pattern was later identified among patients 
with chronic/recurrent lymphadenopathy.88  
 
Kikuchi-Fujimoto Disease. Viral etiology has been 
investigated in Kikuchi-Fujimoto disease (KFD), 
another self-limited benign disorder. Reactivation 
of HHV-6 has been determined serologically94,95 
during the course of KFD, and affected lymph 
nodes have been found to harbor HHV-6 DNA.94 
However, few studies have performed testing for 
HHV-6, and not all data has supported 
involvement of the virus. Twenty lymph nodes 
tested for both EBV and HHV-6, for instance, did 
not reveal any positivity via PCR.96 Similarly, 
only 1/18 lymph node biopsies from another study 
were HHV-6 positive by PCR- as were 2/18 
control lymph nodes from asymptomatic patients 
with papillary thyroid carcinoma who had not 
received chemo/radiotherapy, 1 patient with 
Warthin tumor, and 2 cases of paraganglioma.97 
An earlier study found that the lymph nodes of all 
but one patient were PCR positive, and all samples 
tested by ISH were positive as well. On the other 
hand, the positivity by ISH was not limited to 
these specimens but was also present in patients 
with reactive paracortical hyperplasia (60%), 
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nonspecific lymphadenitis (60%), and tuberculosis 
lymphadenitis (22.2%).98 Because it is often 
difficult to procure tissue samples from healthy 
persons, it is important to note that HHV-6 could 
contribute to illnesses affecting controls or may 
reactivate in response to an illness, which may 
complicate analysis of the role of HHV-6. This 
obstacle, as well as variation in assays, carries the 
potential to skew the interpretation of results. 
 
Ocular Lymphoproliferation. Several 
herpesviruses, including HHV-6, have been 
isolated from ocular tissue removed from patients 
with lymphoproliferative disorders. Whereas 
malignant orbital and conjunctival tissues were 
infrequently positive for the virus,99 23% (mean 
viral load 1.7x103copies/microgram DNA) of 
samples from IgG4-related ophthalmic disease and 
43.9% of samples from reactive lymphoid 
hyperplasia of the ocular adnexa were HHV-6+. 
HHV-6A100 and HHV-6B101 have been linked to 
ocular inflammation, perhaps through persistent 
reactivation and stimulation of immune cells.  
 
Atypical/Unusual Lymphoproliferative 
Disorders and Lymphocytic Infiltration. 
Atypical lymphoproliferative disorders are 
characterized by extensive lymphoma-like 
persistent and/or progressive lymphoproliferation, 
which, while still polyclonal, may progress to 
open malignant lymphoma. It may thus be 
considered a pre-lymphomatous condition.11 
HHV-6 has been cited as a trigger for atypical 
polyclonal lymphoproliferation,11,21 although it is 
more commonly involved in non-neoplastic 
lymphocytosis with lymphocytes that are often 
labeled “atypical” but do not show potential for 
malignant transformation, such as those frequently 
observed during infectious mononucleosis (IM)-
like illnesses. The virus has been detected in 
reactive CD4+ lymphocytes characteristic of these 
illnesses,102 which, though ultimately not 
malignant, can strongly resemble lymphoma.103 
Specifically, HHV-6 has been localized to CD3+ 
and CD4+ T cells in the lymph node, characterized 
by intranuclear eosinophilic viral inclusions and 
bearing resemblance to lymphocytes present in 
Hodgkin’s lymphoma and anaplastic large cell 
lymphoma. Large reactive lymphocytes with a 
sinusal and paracortical distribution have been 
found among eosinophils, plasma cells, and 
scattered immunoblasts.  
Infectious Mononucleosis. HHV-6 has been 
implicated in the pathogenesis of a subset of 
infectious mononucleosis (IM)-like illnesses, as 
indicated by serologic evidence of active infection 
and increased HHV-6 specific IgG titers in the 
absence of active EBV or CMV infection.10,104-106 
Coinfections of HHV-6 and EBV also occur 
during IM and could exacerbate the 
symptoms/disease course.10 While the absolute 
prevalence is unclear, HHV-6 was specified as the 
etiological agent in 5% of 40 adults with IM-like 
illnesses in Japan, after PCR analysis.107,108 As is 
often the case during EBV-mediated IM, HHV-6-
associated IM-like conditions have been 
associated with fatigue, lymphocytosis, 
thrombocytosis, migrating lymphadenopathy, 
headaches, fever, maculopapular rash, and 
hepatosplenomegaly with raised liver enzymes, 
increased immature lymphoid cells, PBMC 
death,109-111 and “atypical” T lymphocytosis 
coinciding with HHV-6 antigen expression.111 The 
effects of reactivation may persist even after 
resolution of active infection; in patients with 
active HHV-6A and IM, the viral DNA load in 
blood peaks within 4 weeks and returns to normal 
by 16 weeks, while prolonged T lymphocytosis 
decreases to normal levels by 24-28 weeks.112 
HHV-6B and untyped HHV-6 DNA has been 
detected in the serum, lymph nodes, and CD4+ T 
cells of skin tissue characterized by “atypical” 
infiltrating CD4+ and CD8+ T cells, by PCR, IHC, 
Southern blot, and ISH.113-115 Examination of 
lymph node tissue revealed transformed 
lymphocytes and immunoblast-like cells, some of 
which were positive for HHV-6, in addition to 
some histiocytes and eosinophils. Of interest, 
instances of HHV-6-associated IM have been 
significantly associated with Downey type III 
lymphocytes (i.e. monocytoid blasts with 
basophilic cytoplasmic granules,108,116 and it 
appears that this type of IM may present with 
certain manifestations relatively unique to HHV-
6.  
The resulting lymphoproliferation observed 
during HHV-6-associated IM-like illnesses has 
been posited to stem from a response by CD8+ T 
cells against HHV-6-infected CD4+ T cells;113 
analysis of the PBMC composition has identified 
35.7% of cells as CD4+ and 52.6% as CD8+. 
HHV-6-specific T cells consist of CD4+ and 
CD8+ cells, but in patients with acute HHV-6 
infection, CD8+ cells may predominate for several 
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months after an initial spike in the CD4+/CD8+ 
ratio.88,117 Taking into consideration the time-
dependent nature of these changes in cellular 
populations, computer models have illustrated that 
acute HHV-6 infection can raise the CD4+/CD8+ 
T cell ratio initially, but there is a subsequent 
sharp decrease as CD4+ cells are removed and 
CD8+ cells proliferate.117 Once HHV-6 has 
infected lymphocytes, the maturation and function 
of the cells are altered. During acute infection, this 
may manifest as an infectious mononucleosis-like 
illness, while during chronic persistent infection, 
chronic fatigue-type cellular changes have been 
observed, as has persistent immature 
lymphocytosis similar to that seen in Canale-Smith 
syndrome.118 
 
Hemophagocytic Syndrome/Hemophagocytic 
Lymphohistiocytosis. Hemophagocytic syndrome/ 
hemophagocytic lymphohistiocytosis (HLH), a 
hyperinflammatory disease marked by activation 
of T lymphocytes and macrophages and driven by 
overproduction of cytokines, may result from 
infection by herpesviruses, including EBV, CMV, 
and HHV-6, and at times, more than one 
virus.119,120 Systemic manifestations during HHV-
6-induced HLH, including CNS dysfunction, 
respiratory distress, multiorgan failure, and 
disseminated intravascular coagulation, are often 
severe and can be fatal.119,121-124 While HLH 
linked to reactivation of HHV-6 has occurred in 
patients with underlying conditions, it has also 
occurred in seemingly healthy individuals.122 
Notably, reactivation is not the only avenue for 
development of hemophagocytosis and HLH, as 
both localized and systemic hemophagocytosis can 
also occur during infancy, and in some cases, it is 
likely a complication of primary infection.125-127 
As in adults, some children who develop HHV-6-
associated HLH may be predisposed to the 
syndrome due to underlying disorders, including 
Wiedemann-Beckwith syndrome124 and beta-
thalassemia.128 
 
Hepatitis and Liver Dysfunction. During HHV-6 
reactivation post-transplant, hepatitis and liver 
dysfunction may develop. Randhawa et al. 
reported a case of HHV-6A-associated 
gastroduodenitis, pancreatitis, and hepatitis in an 
adult heart transplant recipient129 with concomitant 
multinucleate giant cell transformation observed in 
biopsies, and in another instance, giant cell 
hepatitis presumably caused by HHV-6A was 
observed in a liver transplant recipient.130 Both 
species of HHV-6 have shown cell-cell fusion 
capabilities in vitro in lymphocytes and other cells, 
although the response is more robust for HHV-
6A.21,131,132 Cell fusion events and polyploidy are 
associated with malignancies and metastasis.133 
HHV-6 infection has also been associated with an 
increased number of liver allograft infiltrating 
lymphocytes expressing class II antigens, LFA-1, 
and VLA-4,134 and less commonly, the virus is 
found in liver tissue from immunocompetent 
patients with hepatitis135-137 and multiple organ 
failure.138 Among patients with HHV-6-associated 
liver dysfunction, “atypical” activated 
lymphocytes may be present in both the blood and 
infiltrating lymphocytes of the liver.139 
 
DIHS/DRESS. Perhaps the deleterious effects of 
HHV-6-mediated lymphocytic infiltration are 
exemplified best by severe DIHS/DRESS, a 
condition that can mimic malignant lymphoma140-
142 characterized by erythematous rash, organ 
dysfunction, and occasionally organ failure.143 
High level HHV-6 viremia is often found in these 
patients, and HHV-6 DNA and antigen has been 
detected in the CSF of patients with encephalitis 
and hemophagocytosis,143,144 the livers of patients 
with hepatitis and liver failure,143,145 the kidneys of 
patients with renal dysfunction and failure,146,147 
and the bone marrow of patients with 
hemophagocytic syndrome.148,149 HHV-6 is 
thought to contribute to the clinical manifestations 
of DIHS/DRESS, especially the atypical 
lymphocytosis,150 lymphadenitis,141 and 
multiorgan involvement, and viremia is predictive 
of a more severe course and flaring of symptoms, 
including hepatitis and fever,151 as is 
hemophagocytosis.140 Additionally, administration 
of valganciclovir has improved the condition of 
patients with severe DIHS/DRESS.143,147,149 HHV-
6 has been found in hepatocytes143,145,152 and 
tubular epithelial cells of the kidney,146,147 as well 
as in infiltrating lymphocytes, often 
atypical.141,148,152 Notably, the detection of HHV-6  
in these cells has corresponded to severe necrosis 
and dysfunction in the related organs.  
In addition to triggering lymphocyte infiltration 
into organs in DIHS/DRESS, HHV-6 appears to 
disrupt the properties and functions of 
lymphocytes during and after the reaction. 
Laboratory findings include lymphopenia or  
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lymphocytosis, the presence of “atypical” 
hyperbasophilic lymphocytes, and sometimes 
hypogammaglobulinemia, leukocytosis and 
thrombocytopenia.153 Infiltrating atypical 
lymphocytes may be detected in tissue samples, 
and atypical lymphocytosis is present in 27-67% 
of DIHS/DRESS patients.154 Strikingly, in one 
study142 HHV-6 antigen was found to be 
exclusively localized to the Reed-Sternberg-like 
cells of the lymph node, and the cells exhibited 
loss of CD3 expression. In a similar study, HHV-6 
was reportedly present in the majority of large 
infiltrating atypical lymphocytes with prominent 
nuclear inclusions in lymph node biopsies by ISH 
and IHC for p41 early antigen and DR6 and p101k 
late antigens, and again, there was partial loss of 
CD3 expression.141 As in cases of persistent 
lymphocytosis with plasmablastoid and Downey-
type cells in generalized lymphadenopathy and 
IM, both cytoplasmic152 and intranuclear (Figure 
2)148 viral inclusions with a peripheral halo in 
CD3+CD4+ atypical T cells in the lymph node 
have been reported in DIHS/DRESS. In the latter 
case, the cells displaying positivity to HHV-6 
antibodies appeared to be Tregs, which are thought 
to be important in the pathogenesis of 
DIHS/DRESS, as well as the development of 
autoimmunity after resolution of the syndrome, 
when Treg activity is suppressed and Th17 cells 
increase in number significantly.153 In vitro testing 
indicates that HHV-6A154 and HHV-6B155 can 
induce virus-specific Tregs.  
 
Castleman’s Disease. Case reports and some 
larger studies have found HHV-6 in the blood and 
lymph nodes of patients with Castleman’s disease 
(CD) by PCR.156 When the virus identified in 
lymph node biopsies was typed in two cases, it 
corresponded to HHV-6B, and viral loads were 5.5 
and 53.7 copies/microgram DNA.157 In a larger 
cohort, 2/16 (12%) CD patients, both of 
multicentric mixed-type CD, were HHV-6 positive  
by PCR in involved tissues, although they were 
also positive for EBV, with a total of 9 EBV+ 
samples.158 As low-level, latent HHV-6 may be 
found in healthy individuals, both in tissue and in 
blood, it is unclear whether these results implicate 
HHV-6 in the development of CD. 
 
Malignant Lymphoproliferation. 
 
Hodgkin’s Lymphoma. Interesting data has been 
reported on the possible involvement of HHV-6 in 
the nodular sclerosis (NS) subtype of Hodgkin’s 
lymphoma (HL) (Figure 3). Early results finding 
HHV-6 antigens p41 and gp116/64/54 in 
Hodgkin’s disease and Reed Sternberg (RS) cells 
in 37% of biopsies led investigators to hypothesize 
that the virus might contribute to HL through 
dysregulation of the cytokine network and through 
polyclonal stimulations of cellular proliferation.159 
Further investigation revealed the absence of 
HHV-6 DNA by Southern blot, even when 
positive by PCR, absence of the virus in neoplastic 
cells, and no antigen expression by IHC (for 
gp102, p41, and P11G1-G9C7), with the exception 
of 2/2 cases of NSHL with interfollicular pattern, 
which were positive for HHV-6 MAb in residual 
germinal centers.160 Along the same lines, HHV-6 
early antigen p41 was not observed in viable RS 
cells from lymph nodes positive by PCR in a later 
study, but “mummified” RS cells did show 
positivity in the two cases with the highest copy 
numbers.85 Later studies, however, detected HHV-
6 in lymph nodes of 41.9% of NSHL lymph nodes 
at a mean viral load of 6,711.4 copies/microgram 
DNA, 12/13 of which were typed as HHV-6B, 
while tissues from 6 patients with other HL 
subtypes were negative.161 The detection of HHV-
6 DNA in NSHL cases spurred further 
examination of additional lymph nodes, and in 
another cohort, the virus was identified in a 
majority (83.6%) of tumor samples from patients 
with NSHL, the predominant type of HL in the 
group.162 EBV coinfections accounted for 49.3% 
of total NS cases, and in coinfected tissues, viral 
loads of EBV and HHV-6 were higher than in the 
specimens with a single infection (mean 47,666.5 
copies HHV-6/microgram DNA in NS cases vs. 
271.4 copies/microgram DNA), suggesting either 
an immunosuppressive environment favoring viral 
reactivation, or  potentiation  of   viral   replication 
through simultaneous activity. In the same study, 
HHV-6 was also found among 5/10 patients with 
mixed-cellularity HL, one of two lymphocyte-
depleted HL, and in the only patient with 
lymphocyte-predominance HL.   
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Figure 2A 
 
Figure 2B 
 
Figure 2. HHV-6 in drug induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.  
A. Histopathology and immunohistochemistry of the lymph node. (A and B) Hematoxylin and eosin staining. Low (A) and high (B) 
magnification views of the cervical lymph node showed diffuse infiltration of large and blastic lymphoid cells with inclusion bodies. 
Intranuclear inclusion bodies were eosinophilic and had a halo (B). (C–E) Immunostaining. The large cells with intranuclear inclusion bodies 
were positive for HHV-6-IE (C). The HHV-6-infected cells were positive for CD25 (D) and FoxP3 (E)(Mine et al. 2014).148 
B. Histopathology and immunohistochemistry of the lymph node. At the cortex of lymph node, large and isolated cells were seen with 
hematoxylin-eosin staining (A).Many of these isolated cells were positive for HHV-6-IE and were scattered throughout the nodule (B). 
CD21 immunostaining showed follicular dendritic cells that presented a mesh-work like structure (C and D), in contact with several of the 
large lymphocytes with inclusion bodies (D). Double immunofluorescence staining showed HHV-6-IEpositive cells expressing CD3, but not 
CD20 (E and F). Immunostaining showed that the large lymphocytes with inclusion bodies were CD4(+) and CD8(−) (G and H)(Mine et al. 
2014).148 
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Figure 3A 
 
Figure 3B 
a)  b)  
c)  
Figure 3C 
 
Figure 3. HHV-6 in Hodgkin’s lymphoma. 
A. a) HHV-6A in nodular sclerosis Hodgkin’s lymphoma. Hodgkin’s lymphoma, nodular sclerosing type: Left, H&E histology. Original 
magnification x250; b) Right HHV-6 DNA (in situ hybridization pZVH14). Original magnification x250. pZVH14 probe used was designed 
by and obtained from Dr. Steve Josephs at NCI/NIH. It was obtained from HHV-6A (GS Strain), and was also cross-hybridizes with HHV-
6B. Probe was labelled with alkaline phosphatase, and the APAAP reaction was used (APAAP: alkaline phosphatase anti alkaline 
phosphatase) to visualize its tissues were subjected to in-situ-hybridization. The reaction was sensitive and highly specific as repeatedly 
proven by isolating HHV-6A in HSB2 cells (isolation in MOLT3 cells for HHV-6B remained negative) (With permission from G. Krueger et 
al.). 
B. a) Presence of HHV-6 p41 by immunohistochemistry. Cytoplasmic staining of numerous large cells using a monoclonal antibody to 
HHV-6 p41 (3E3 clone) among NSHL specimens. 
b). HHV-6 U94 detection by immunohistochemistry. Staining with monoclonal antibody to HHV-6 U94 reveals positivity in the 
cytoplasm of numerous large cells. 
c). Presence of HHV-6 by colorimetric in-situ hybridization. HHV-6 DNA present in the nuclei of both small and large cells. (With 
permission from Dr. David Hudnall, Yale University, New Haven, CT, USA). 
C. HHV-6 U94 PCR of Hodgkin’s lymphoma. Twenty seven of 31 (87%) HL cases were positive for HHV-6 using primers to the U94 
gene. The 19 lanes in the top gel are loaded with PCR product from 19 cases of HL. The 19 lanes in the bottom gel are loaded (from left to 
right) with PCR product from an additional 12 cases of HL, one empty lane, two positive controls (HHV-6A, HHV-6B), one empty lane, a 
negative (water) control, and two empty lanes. Viral load appears to vary tremendously from case to case - in 14 cases the viral load is quite 
high, while in another 13 cases the viral load is very low (Siddon et al. 2012).165 
 
Using IHC with antibody that appears to be 
reactive to both HHV-6 species, the same team 
later targeted the DR7 oncoprotein, a product of 
the ORF-1 gene that is able to bind and inactivate 
the tumor suppressor p53,163 which was found in 
the Reed-Sternberg (RS) cells of 74% of EBV-
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negative HL patients whose lymph nodes had 
previously been found HHV-6 positive by qPCR 
(n=38; 36 NSHL).164 The protein was exclusively 
localized in RS cells, which were CD30+, in 61% 
of cases. Similarly, exclusive staining for DR7B in 
RS cells was observed in 6/9 NSHL cases that 
were both EBV and HHV-6+. The three remaining 
cases showed positivity in RS and infiltrating 
cells, and all nine showed positivity for LMP-1, an 
EBV oncoprotein. A tenth EBV/HHV-6+ patient 
with mixed-cellularity HL only stained for LMP-1 
in RS cells, while DR7B was only identified in 
infiltrating cells. RS cells were positive for 
gp116/64/54 in 15 EBV negative patients. 
Notably, positive staining of gp116/64/54 was 
observed significantly more frequently (p=0.0154) 
among patients with stage III and IV HL compared 
to those at stages I and II.  
Via PCR, the prevalence of HHV-6 in 31 
additional NSHL lymphoid samples was similar to 
the rate of detection among tissues from patients 
with reactive lymphoid hyperplasia (87% vs 83%, 
respectively).165 However, IHC analysis revealed 
HHV-6 whole lysate in numerous RS cells in 48% 
of cases, and early and late antigen was also found 
in scattered RS cells. Multiple copies of the virus 
were present in some RS cells, suggesting that 
active replication was taking place. Of the samples 
that were typed, HHV-6B was present singly in 3 
cases, HHV-6A was present in 4, and HHV-6A/B 
coinfection was found in 3. EBV was detected in a 
total of 5 cases of 21 tested, and EBV/HHV-6 
coinfections were detected in RS cells of 3. Of 
interest, the mean age of patients with HHV-6+ 
RS cells was 23 years, while those with EBV+ RS 
cells had a mean age of 47 years (p=0.073). While 
examination of more cases of mixed cellularity HL 
is warranted, currently, immunohistochemical 
findings most strongly suggest that an association 
may exist between HHV-6 and the NS subtype of 
HL.  
 
Non-Hodgkin’s Lymphoma. As HHV-6 was 
initially isolated from HIV+ patients with 
malignancies, including non-Hodgkin’s lymphoma 
(NHL), several early studies focused on this 
population, finding the virus in 4.8-32% of tumor 
samples.13,14,84,166 Direct HHV-6-mediated 
oncogenic activity has not been observed in 
NHL,11 and the viral antigen has not been found in 
the neoplastic cells,85 but rather, it has been found 
to be present in infiltrating cells of affected tissues 
as well as in blood samples.167 However, evidence 
suggests that the virus may act in conjunction with 
other oncogenic agents, including other viruses, to 
modulate the lymph node microenvironment and 
contribute to the characteristic lymphocytic 
proliferation.85 Case reports, for instance, have 
documented a potential interaction between HHV-
6 and HHV-8 in diffuse large B-cell lymphoma 
(DLBCL). Upon analyzing affected tissues of two 
patients, one with nongerminal B-cell-like DLBCL 
and the other with primary cutaneous DLBCL, 
HHV-6 and HHV-8 were simultaneously present 
in the nucleoli of lymphoma cells. Notably, HHV-
6 has shown the capacity to induce expression of 
HHV-8 lytic phase mRNA and proteins in BCBL-
1 cells.168 Of interest, HHV-6B was also identified 
among 30.8% of a collection of DLBCL lymph 
nodes at a mean viral load of 1,140.7 
copies/microgram DNA.161 In comparison, 23.1% 
of follicular lymphoma samples were positive, but 
the mean copy number was only 39, and of the 
other NHL lymphomas tested, only 1 (of 4) 
peripheral T-cell lymphoma had over 
91copies/microgram DNA, with 3,380 copies. In a 
similar study, 3/5 T-cell lymphoma lymph nodes 
were HHV-6 (2 HHV-6B, 1 unclassified) positive, 
with viral loads of 9.1, 60.4, and 810 
copies/microgram DNA.157 
Similarly, EBV coinfections have frequently 
been observed in HHV-6+ NHL lymphoid 
biopsies;169-171 one study, for example, found 57% 
of HHV-6+ angioimmunoblastic T cell lymphoma/ 
angioimmunoblastic lymphadenopathy (AITL/ 
AILD) lymph nodes to be coinfected with EBV.172 
In a separate cohort, 79% of HHV-6B+ lymph 
nodes were EBV+, with the highest HHV-6B viral 
loads in biopsies with pattern III histology 
(median 40 copies/1000 cells).19 Moreover, all of 
the coinfected samples showed pattern II or III 
histology, with the majority falling under pattern 
III. However, expression of HHV-6 antigens in 
proliferating T lymphocytes of AILD patients has 
not been observed.85 
An inherited, chromosomally integrated form of 
either HHV-6A or HHV-6B, known as ciHHV-6 
or iciHHV-6, is present in about 1% of the 
population. Two intriguing case reports have 
documented ciHHV-6+ patients with NHL: One 
patient, with DLBCL and ciHHV-6 on 
chromosome 17p, developed marker chromosomes 
that were also ciHHV-6+,173 while the other 
individual, who carried ciHHV-6A on 
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chromosome 19q, developed a primary effusion-
like lymphoma characterized by an absence of any 
integrated HHV-6.174 It is possible that ciHHV-6 
may have the potential to trigger lymphoma by 
affecting chromosomal stability. 
 
Lymphocytic Leukemia. Although HHV-6 has 
been detected in the blood175-176 and bone marrow 
of patients with lymphocytic leukemia, and 
heightened titers of HHV-6 antibody have been 
observed in blood samples,177-179 a role for the 
virus in this type of cancer is not well supported. 
In contrast with a later publication,180 one study 
found high rates of HHV-6A in blood and bone 
marrow samples- 43.8% of B-ALL samples, 
52.4% of B-CLL samples, and only less than 10% 
of MM.181 HHV-6 p41 antigen has been detected 
in nearly half of bone marrow samples from 
patients with myelodysplasia by IHC,182 but in 
cases of leukemia, detection of HHV-6A/HHV-6B 
in the bone marrow only by nested PCR and not 
via standard PCR, or at low copy numbers by 
qPCR,175 has suggested that HHV-6 present in the 
samples is likely latent.183 Moreover, when 
quantified, viral loads both in blood and in bone 
marrow, have been found to be lower at diagnosis 
than at remission.175,180,181 As the virus can infect 
bone marrow progenitors and reactivate under 
immunosuppressive conditions, the presence of the 
virus as it was detected in these instances likely 
did not impact the course of leukemia.  
 
Discussion. The interactions of chronic active 
HHV-6 infection with the immune system may 
result in a variety of clinical diseases including 
aplasia, autoimmune disorders (e.g. Sjögren’s 
syndrome, lupus erythematosus, scleroderma), and 
lymphoproliferation. These manifestations reflect 
the disturbed balance between viral persistence 
and the host’s defense status.184,185 The current 
overview focuses only on lymphoproliferative 
disorders in order not to further complicate the 
report. 
HHV-6 may contribute to several 
benign/reactive lymphoproliferative disorders by 
spurring a dysfunctional immune response or 
through dysregulation of cytokines and other 
immune mediators. It is probable that HHV-6A 
and HHV-6B are two of many potential triggers 
for these disorders, but immunohistochemical 
analysis may reveal characteristic patterns of viral 
expression and cellular features in cases associated 
with either virus. As more instances of HHV-6 
associated lymphoproliferation are described, 
clinical parameters might also be found that are 
indicative of HHV-6 involvement. Both primary 
infection and reactivation are able to induce 
“atypical” lymphocytosis, in which activated cells 
may appear abnormal and may even resemble 
transformed, malignant cells. Under some 
circumstances, HHV-6A/HHV-6B are also 
capable of inducing organ dysfunction, with 
lymphocytic infiltration often observed in the 
affected organs. Because both species of HHV-6 
can infect a variety of cells, active infection in 
tissues may result in an immune response toward 
the infected tissues, resulting in lymphocytic 
infiltration, or active infection of lymphocytes 
may trigger an inflammatory reaction and drive 
lymphocytic infiltration directly. Although a role 
for HHV-6 in many lymphomatous malignancies 
is not strongly supported, evidence points to a 
potential contribution of the virus in certain 
Hodgkin’s lymphomas of the nodular sclerosis 
type. The wider use of quantitative PCR and 
immunohistochemical techniques has enabled 
more accurate interpretation of viral involvement 
in lymphoproliferative conditions, and the 
continued utilization of these techniques will be 
vital to expanding the knowledge of their 
association between HHV-6 and these disorders, 
as well as uncovering the mechanisms behind 
them. Ultimately, further research is needed to 
elucidate the immunomodulatory capabilities of 
HHV-6A and HHV-6B as they relate to the 
functionality of lymphocytes and to better define 
their roles in lymphoproliferative diseases, both 
during acute infection and persistent reactivation. 
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